Key points for investors:
- Financial results: Q1 2026 revenue was $22.5M (up 6.4% YoY), beating Q1 guidance. Q1 adjusted EBITDA was negative $1.5M; net loss was $3.3M. Cash and equivalents were $35.5M with total liquidity of $39.4M. Subscription MRR was ~$1.0M at quarter end. Subscription count exceeded 115,000 paying subscribers in Q1.
- Guidance and profitability focus: Management narrowed full-year 2026 revenue guidance to $118M–$122M (down from prior $126M–$130M) to exit lower-margin, high-burden geographies and channels. They raised full-year adjusted EBITDA guidance to $7M–$9M (250%–350% growth YoY), emphasizing a deliberate trade-off of lower near-term revenue for improved operating leverage and profitability.
- Strategic priorities: CEO Kurt Workman is back as CEO and outlined three priorities — (1) a subscription-first push (Owlet360 and telehealth), (2) sharpened focus on high-value core markets (U.S. and existing international markets) and postpone entries into India/Hong Kong/Singapore, and (3) operational efficiency and cost discipline (pausing new global clearances, deferring low-ROI projects, and reducing planned headcount additions).
- Subscription & product traction: Owlet360 adoption is strong — ~34% penetration among U.S. Dream Sock users in Q1, 115k+ paying subscribers, and MRR of $1M. Management plans camera-specific subscription features (Dream Sight Extended Clips, white noise) and has launched Owlet OnCall telehealth in-app for select users to test and scale.
- Unit trends and market opportunity: U.S. sell-through for Sock and Duo grew 10.5% YoY in Q1 (Duo +45%, Dream Sock +3%); Owlet grew while category declined. Q2-to-date sell-through is strong (+30% vs prior year for both Duo and Dream Sock), though this stronger Q2 has not been baked into full-year guidance yet. International revenue grew 22% YoY in Q1; some markets show high penetration (e.g., Czech Republic ~9% of newborns).
- Margins and cost drivers: Q1 overall gross margin was 54.5% (above guidance) and subscription gross margin expanded to 67.4%. Tariffs remain a headwind but estimated tariff baseline improved to ~15% from prior higher levels. Operating expenses increased (to $17.7M) driven by compensation and stock‑based comp; management is reprioritizing and removing planned headcount increases to improve efficiency.
- Longer-term thesis: Management frames Owlet as an AI-anchored pediatric health platform with a large, proprietary pediatric dataset, positioning subscription and telehealth as levers to extend customer LTV (targeting up to a 4-year household subscription window across multiple children) and to compound recurring revenue over time.
Sign In
Buy OWLT
